Latisse


latisse before

Latisse is the trade name for a solution of bimatoprost that has been created for the treatment of hypotrichosis from a purely cosmetic perspective and is marketed in America. Hypotrichosis is when a patient feels that they have inadequate or not enough eyelashes. By applying bimatoprost/Latisse to the base of the eyelash, it causes it to grow longer, thicker and darker.

Latisse comes with disposable applicators and is in a smaller dropper bottle.

Allergan, the company that produced the drug, gained United States Federal Drugs Association (FDA) approval on December 5th 2008.

To gain FDA approval bimatoprost had to undergo studies into its safety and efficacy for this cosmetic application. It was found to be safe and effective at growing eyelashes. The average result was a 25% increase in length, 106% increase in thickness and 18% darker lashes. latisse after

A lot of press coverage has been generated on the potential for bimatoprost to cause iris discolouration. During the trials, no incident of iris discolouration has been demonstrated and, at the time of writing, no evidence of this effect occurring in a cosmetic application has been found by Dr . In 2012 alone, 3.5 million kits of Latisse were sold with no documented proof of iris changes.



Mylash is a British company

He has a keen interest in hair growth and non-surgical ways to improve this for cosmetic purposes and post-chemotherapy.

Dr Walker has been published in the Journal of Plastic and Reconstructive Surgery and has contributed his professional opinions to articles in Hello magazine, Elle, Grazia and many more.

Mylash continues to only use British based medical doctors to ensure a safe service that offers you clinically proven treatments.

Testimonials

Read testimonials from some of our celebrity clients and leading journalists.

Testimonials

Press coverage

Our service has been featured in articles in many major press publications.

Press coverage

Articles

Read articles on the science behind the treatment and the latest developments.

Read articles